JP2001512478A5 - - Google Patents

Download PDF

Info

Publication number
JP2001512478A5
JP2001512478A5 JP1998536611A JP53661198A JP2001512478A5 JP 2001512478 A5 JP2001512478 A5 JP 2001512478A5 JP 1998536611 A JP1998536611 A JP 1998536611A JP 53661198 A JP53661198 A JP 53661198A JP 2001512478 A5 JP2001512478 A5 JP 2001512478A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1998536611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001512478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/021996 external-priority patent/WO1998036755A1/en
Publication of JP2001512478A publication Critical patent/JP2001512478A/ja
Publication of JP2001512478A5 publication Critical patent/JP2001512478A5/ja
Abandoned legal-status Critical Current

Links

JP53661198A 1997-02-19 1997-12-01 糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物 Abandoned JP2001512478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
US60/038,224 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
JP2001512478A JP2001512478A (ja) 2001-08-21
JP2001512478A5 true JP2001512478A5 (enExample) 2005-06-16

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53661198A Abandoned JP2001512478A (ja) 1997-02-19 1997-12-01 糖尿病のためのスルホニル尿素−グリタゾン相乗的組み合わせ物

Country Status (29)

Country Link
US (2) US5859037A (enExample)
EP (1) EP0957923A1 (enExample)
JP (1) JP2001512478A (enExample)
KR (1) KR20000071179A (enExample)
CN (1) CN1244801A (enExample)
AR (1) AR011829A1 (enExample)
AU (1) AU741215B2 (enExample)
BG (1) BG103671A (enExample)
BR (1) BR9714505A (enExample)
CA (1) CA2272478A1 (enExample)
CZ (1) CZ289299A3 (enExample)
EA (1) EA199900725A1 (enExample)
EE (1) EE9900345A (enExample)
GT (1) GT199800037A (enExample)
HN (1) HN1997000167A (enExample)
HU (1) HUP0001528A3 (enExample)
IL (1) IL130027A (enExample)
IS (1) IS5058A (enExample)
NO (1) NO993982D0 (enExample)
NZ (1) NZ336002A (enExample)
PA (1) PA8447401A1 (enExample)
PE (1) PE74399A1 (enExample)
PL (1) PL335166A1 (enExample)
SK (1) SK111899A3 (enExample)
SV (1) SV1998000010A (enExample)
TR (1) TR199902033T2 (enExample)
UY (1) UY24893A1 (enExample)
WO (1) WO1998036755A1 (enExample)
ZA (1) ZA981343B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
EP0999845B1 (en) * 1997-06-18 2007-02-14 SmithKline Beecham plc Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ID23372A (id) * 1997-06-18 2000-04-20 Smithkline Beecham Plc Pengobatan diabetes dengan tiazolidindion dan metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ES2218338T3 (es) * 2000-04-13 2004-11-16 Pfizer Products Inc. Efecto sinergico de gliburida y milrinona.
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4694841B2 (ja) 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
LT2868315T (lt) 2007-12-04 2017-09-25 Biogen Chesapeake Llc Patobulintos kompozicijos ir liofilizacijos būdai bei gauti liofilizatai
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
MX380878B (es) 2008-12-04 2025-03-12 Chongxi Yu Composiciones de alta penetracion y sus aplicaciones.
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
MX2012005500A (es) * 2009-11-13 2012-08-03 Toray Industries Agente terapeutico o profilactico para diabetes.
AU2011257964B2 (en) * 2010-05-24 2014-10-30 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
BR112013018469B1 (pt) 2011-01-19 2022-03-03 Fractyl Health, Inc Dispositivos e métodos para tratamento de tecidos
EP2782586A4 (en) * 2011-11-23 2015-07-01 Ozstar Therapeutics Pty Ltd ENHANCED SYNERGIC ANTIDIABETIC COMPOSITIONS
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
AU2013226062B2 (en) 2012-02-27 2017-10-19 Fractyl Health, Inc. Heat ablation systems, devices and methods for the treatment of tissue
AU2013249043B2 (en) 2012-04-19 2017-04-27 Fractyl Health, Inc. Tissue expansion devices, system and methods
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
EP3071286B1 (en) 2013-11-22 2024-01-03 Fractyl Health, Inc. Systems for the creation of a therapeutic restriction in the gastrointestinal tract
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
WO2016011269A1 (en) 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
KR102854572B1 (ko) 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
IL294671A (en) 2020-01-15 2022-09-01 Fractyl Health Inc Automated tissue handling devices, systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Similar Documents

Publication Publication Date Title
JP2001508247A5 (enExample)
JP2001514764A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2001503295A5 (enExample)
JP2001503896A5 (enExample)
JP2000501324A5 (enExample)
JP2001504104A5 (enExample)
JP2000500055A5 (enExample)
JP2001512478A5 (enExample)
JP2000504625A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000502570A5 (enExample)
JP2000500912A5 (enExample)
JP2000511877A5 (enExample)
JP2000514109A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000500184A5 (enExample)
JP2000500318A5 (enExample)